Dr. Reddy's Laboratories Limited (RDY)
USD 14.55
(0.48%)
USD 14.55
(0.48%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | 55.68 Billion INR | 23.56% |
| 2023 | 45.06 Billion INR | 91.22% |
| 2022 | 23.56 Billion INR | 36.72% |
| 2021 | 17.23 Billion INR | -11.59% |
| 2020 | 19.49 Billion INR | 3.74% |
| 2019 | 18.79 Billion INR | 91.67% |
| 2018 | 9.8 Billion INR | -18.55% |
| 2017 | 12.03 Billion INR | -39.84% |
| 2016 | 20.01 Billion INR | -9.77% |
| 2015 | 22.17 Billion INR | 3.1% |
| 2014 | 21.51 Billion INR | 28.22% |
| 2013 | 16.77 Billion INR | 17.63% |
| 2012 | 14.26 Billion INR | 29.18% |
| 2011 | 11.04 Billion INR | 933.71% |
| 2010 | 1.06 Billion INR | 120.67% |
| 2009 | -5.16 Billion INR | -210.47% |
| 2008 | 4.67 Billion INR | -49.96% |
| 2007 | 9.34 Billion INR | 472.48% |
| 2006 | 1.63 Billion INR | 672.98% |
| 2005 | 211.26 Million INR | -91.48% |
| 2004 | 2.47 Billion INR | -29.6% |
| 2003 | 3.52 Billion INR | -28.35% |
| 2002 | 4.91 Billion INR | 564.92% |
| 2001 | 739.27 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | 13.07 Billion INR | -5.21% |
| 2024 Q3 | 13.78 Billion INR | -6.83% |
| 2024 Q1 | 14.02 Billion INR | 46.22% |
| 2024 Q2 | 14.8 Billion INR | 5.53% |
| 2024 FY | 55.68 Billion INR | 23.56% |
| 2023 Q3 | 12.47 Billion INR | 12.07% |
| 2023 Q4 | 9.59 Billion INR | -23.09% |
| 2023 FY | 45.06 Billion INR | 91.22% |
| 2023 Q2 | 11.12 Billion INR | -6.3% |
| 2023 Q1 | 11.87 Billion INR | 1257.26% |
| 2022 Q3 | 7.06 Billion INR | -28.78% |
| 2022 Q4 | 875 Million INR | -87.62% |
| 2022 Q2 | 9.92 Billion INR | 73.79% |
| 2022 Q1 | 5.7 Billion INR | 3.13% |
| 2022 FY | 23.56 Billion INR | 36.72% |
| 2021 Q1 | 5.79 Billion INR | -24.2% |
| 2021 FY | 17.23 Billion INR | -11.59% |
| 2021 Q2 | 7.62 Billion INR | 31.59% |
| 2021 Q3 | 198 Million INR | -97.4% |
| 2021 Q4 | 5.53 Billion INR | 2695.45% |
| 2020 Q1 | 6.62 Billion INR | 52.58% |
| 2020 FY | 19.49 Billion INR | 3.74% |
| 2020 Q4 | 7.64 Billion INR | 234.14% |
| 2020 Q3 | -5.69 Billion INR | -152.15% |
| 2020 Q2 | 10.92 Billion INR | 64.83% |
| 2019 Q2 | 5.03 Billion INR | 10.46% |
| 2019 Q1 | 4.56 Billion INR | 50.93% |
| 2019 FY | 18.79 Billion INR | 91.67% |
| 2019 Q3 | 4.85 Billion INR | -3.69% |
| 2019 Q4 | 4.34 Billion INR | -10.47% |
| 2018 Q2 | 2.84 Billion INR | 382.06% |
| 2018 FY | 9.8 Billion INR | -18.55% |
| 2018 Q4 | 3.02 Billion INR | -9.63% |
| 2018 Q3 | 3.34 Billion INR | 17.37% |
| 2018 Q1 | 591 Million INR | -81.09% |
| 2017 FY | 12.03 Billion INR | -39.84% |
| 2017 Q3 | 4.7 Billion INR | 59.36% |
| 2017 Q2 | 2.95 Billion INR | 133.57% |
| 2017 Q1 | 1.26 Billion INR | 69.3% |
| 2017 Q4 | 3.12 Billion INR | -33.52% |
| 2016 Q2 | 7.21 Billion INR | 15.36% |
| 2016 Q3 | 5.79 Billion INR | -19.76% |
| 2016 FY | 20.01 Billion INR | -9.77% |
| 2016 Q1 | 6.25 Billion INR | 20.58% |
| 2016 Q4 | 746 Million INR | -87.12% |
| 2015 FY | 22.17 Billion INR | 3.1% |
| 2015 Q2 | 5.74 Billion INR | 4.31% |
| 2015 Q1 | 5.5 Billion INR | 14.29% |
| 2015 Q4 | 5.18 Billion INR | -9.68% |
| 2015 Q3 | 5.74 Billion INR | 0.07% |
| 2014 FY | 21.51 Billion INR | 28.22% |
| 2014 Q4 | 4.81 Billion INR | -22.13% |
| 2014 Q3 | 6.18 Billion INR | -10.41% |
| 2014 Q2 | 6.9 Billion INR | 91.25% |
| 2014 Q1 | 3.61 Billion INR | -36.77% |
| 2013 Q4 | 5.7 Billion INR | 50.95% |
| 2013 Q1 | 3.36 Billion INR | -1.96% |
| 2013 Q2 | 4.07 Billion INR | 21.25% |
| 2013 FY | 16.77 Billion INR | 17.63% |
| 2013 Q3 | 3.78 Billion INR | -7.17% |
| 2012 Q1 | 2.62 Billion INR | -21.46% |
| 2012 Q3 | 5.13 Billion INR | 66.7% |
| 2012 FY | 14.26 Billion INR | 29.18% |
| 2012 Q4 | 3.42 Billion INR | -33.21% |
| 2012 Q2 | 3.07 Billion INR | 17.17% |
| 2011 Q2 | 2.86 Billion INR | 36.83% |
| 2011 FY | 11.04 Billion INR | 933.71% |
| 2011 Q4 | 3.34 Billion INR | 22.44% |
| 2011 Q3 | 2.73 Billion INR | -4.74% |
| 2011 Q1 | 2.09 Billion INR | 25.89% |
| 2010 Q1 | 2.44 Billion INR | 125.01% |
| 2010 Q2 | 2.17 Billion INR | -11.12% |
| 2010 Q3 | -5.21 Billion INR | -340.08% |
| 2010 Q4 | 1.66 Billion INR | 131.91% |
| 2010 FY | 1.06 Billion INR | 120.67% |
| 2009 Q3 | 2.44 Billion INR | 132.27% |
| 2009 FY | -5.16 Billion INR | -210.47% |
| 2009 Q4 | -9.77 Billion INR | -499.88% |
| 2009 Q2 | 1.05 Billion INR | -21.8% |
| 2009 Q1 | 1.34 Billion INR | 31.36% |
| 2008 Q3 | -847.38 Million INR | -137.76% |
| 2008 FY | 4.67 Billion INR | -49.96% |
| 2008 Q1 | 1.82 Billion INR | -43.88% |
| 2008 Q2 | 2.24 Billion INR | 22.73% |
| 2008 Q4 | 1.02 Billion INR | 220.92% |
| 2007 Q1 | 1.4 Billion INR | 704.87% |
| 2007 Q3 | 1.88 Billion INR | -32.42% |
| 2007 Q2 | 2.78 Billion INR | 99.15% |
| 2007 FY | 9.34 Billion INR | 472.48% |
| 2007 Q4 | 3.25 Billion INR | 72.92% |
| 2006 Q2 | 886.2 Million INR | 155.17% |
| 2006 Q1 | 347.3 Million INR | 175.16% |
| 2006 FY | 1.63 Billion INR | 672.98% |
| 2006 Q4 | -231.46 Million INR | -136.85% |
| 2006 Q3 | 628.12 Million INR | -29.12% |
| 2005 Q1 | 173.37 Million INR | 3.53% |
| 2005 Q4 | -462.08 Million INR | -1351.81% |
| 2005 Q3 | 36.91 Million INR | -92.86% |
| 2005 FY | 211.26 Million INR | -91.48% |
| 2005 Q2 | 517.01 Million INR | 198.2% |
| 2004 Q1 | 795.25 Million INR | 19.3% |
| 2004 FY | 2.47 Billion INR | -29.6% |
| 2004 Q3 | 591.55 Million INR | -36.46% |
| 2004 Q4 | 167.46 Million INR | -71.69% |
| 2004 Q2 | 931.02 Million INR | 17.07% |
| 2003 Q2 | 953.23 Million INR | -21.4% |
| 2003 FY | 3.52 Billion INR | -28.35% |
| 2003 Q1 | 1.21 Billion INR | 16.14% |
| 2003 Q3 | 694.05 Million INR | -27.19% |
| 2003 Q4 | 666.59 Million INR | -3.96% |
| 2002 Q1 | 440.2 Million INR | 0.0% |
| 2002 Q2 | 2.12 Billion INR | 382.24% |
| 2002 FY | 4.91 Billion INR | 564.92% |
| 2002 Q4 | 1.04 Billion INR | -20.26% |
| 2002 Q3 | 1.3 Billion INR | -38.31% |
| 2001 FY | 739.27 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | -83.99 Million USD | 66396.001% |
| Bausch Health Companies Inc. | -592 Million USD | 9506.081% |
| Catalent, Inc. | -1.04 Billion USD | 5438.83% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 7422.025% |
| Elanco Animal Health Incorporated | -1.23 Billion USD | 4623.477% |
| Perrigo Company plc | -12.7 Million USD | 438556.693% |
| Teva Pharmaceutical Industries Limited | -559 Million USD | 10061.36% |
| Zoetis Inc. | 2.34 Billion USD | -2275.597% |